Walter M. Stadler to Bortezomib
This is a "connection" page, showing publications Walter M. Stadler has written about Bortezomib.
Connection Strength
0.074
-
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
Score: 0.057
-
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr; 25(2):181-5.
Score: 0.017